Lucid Diagnostics Inc. announced Q4 and full year 2025 financial results, reporting $1.5 million in EsoGuard revenue for Q4 and processing 3,664 tests, alongside a VA contract award and positive real-world data for EsoGuard and EsoCheck. The company reported a GAAP net loss of $16.3 million or $(0.12) per share for Q4, with cash of $34.7 million at year-end.
Key takeaways
Processed 3,664 EsoGuard tests in Q4 2025
Recognized $1.5 million EsoGuard revenue in Q4 2025
Awarded U.S. Department of Veterans Affairs contract for EsoGuard at $1,938 Medicare-aligned pricing across 170 VA medical centers
Q4 2025 GAAP net loss $16.3 million or $(0.12) per share; non-GAAP adjusted loss $12.6 million or $(0.10) per share
Cash and cash equivalents $34.7 million as of December 31, 2025
Full year 2025 revenue $4.706 million vs $4.346 million in 2024